Atopic Dermatitis
- Compensation to be determined
- 13 visits (enrollment open)
A. ≥ 12yo to <18, weight > 40kg (adolescent group)
B. ≥ 18yo (adult group)
Male or Female
Smoker & Non-Smoker
ShareDescription
The main purpose of this study is to determine if lebrikizumab is a safe and effective treatment for moderate-to-severe atopic dermatitis (AD) in patients who have been treated with dupilumab previously. The main reason for you to take part in this study is not to treat you for your condition but to help researchers understand:
- Whether taking lebrikizumab helps patients with AD who were previously treated with dupilumab , and
- The safety of lebrikizumab and any side-effects you might have when you takelebrikizumab.
Dupilumab is a monoclonal antibody used to treat AD patients. Lebrikizumab is an
investigational/experimental drug, which means that it has not been approved for routine clinical use or
for the use described in this study by the United States Food and Drug Administration (FDA). The FDA is
allowing the use of this lebrikizumab for research.
